The recall involves Lot# GMML24026A (NDC# 29300-415-19) with an expiration date of September 2027. Unichem Pharmaceuticals is recalling 1 lot of Cyclobenzaprine Hydrochloride Tablets USP, 10mg due to ...
Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors. Apace ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A sublingual tablet form of the muscle relaxant ...
Please provide your email address to receive an email when new articles are posted on . Tonmya significantly reduced daily pain vs. placebo in a phase 3 trial in fibromyalgia. Fast track designation ...
08/27/2025– East Brunswick, NJ, Unichem Pharmaceuticals (USA), Inc. is voluntarily recalling one (1) lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg, to the consumer level. The Cyclobenzaprine ...
Details concerning the Cyclobenzaprine combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, ...
CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...
The FDA has approved cyclobenzaprine hydrochloride sublingual tablets (Tonmya, Tonix Pharmaceuticals), a first-in-class, nonopioid treatment for adults with fibromyalgia, a chronic pain syndrome that ...
CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback